A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC
This multi-center, open label phase II clinical study is performed in patients with recurrent metastatic squamous cell carcinoma of the head and neck progressed on prior anti-PD-1 mab ± platinum-based chemotherapy. This study is investigating the safety and efficacy of SI-B001 as a single agent in patients.
Head and Neck Squamous Cell Carcinoma
DRUG: SI-B001
ORR, Objective Response Rate, Up to 2 weeks
DOR, Duration of Response, Up to 2 years|PFS, Progression-free Survival, Up to 2 years|DCR, Disease Control Rate, Up to 2 years|OS, Overall survival, Up to 2 years|TEAE, Treatment-Emergent Adverse Event, Up to 2 years|Tmax, Time to maximum serum concentration, Up to 2 years|Cmax, maximum serum concentration, Up to 2 years|Ctrough, minimum serum concentration, Up to 2 years|ADA, anti-SI-B001 antibody, Up to 2 years
This multi-center, open label phase II clinical study is performed in patients with recurrent metastatic squamous cell carcinoma of the head and neck progressed on prior anti-PD-1 mab ± platinum-based chemotherapy. This study is investigating the safety and efficacy of SI-B001 as a single agent in patients.